DaVita Inc. (DVA)
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Do Options Traders Know Something About DaVita Stock We Don't?
Investors need to pay close attention to DVA stock based on the movements in the options market lately.
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Is DaVita (DVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
DaVita Q2 Earnings Call Highlights
DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.
